Reports Q4 revenue $79.545M, consensus $75.64M. "It has been exciting to build on our strong initial launch by doubling ORLADEYO revenues in our second year, and to see the expanding global reach of an oral, once-daily therapy that is changing the lives of patients with HAE and their families," said Jon Stonehouse, president and chief executive officer of BioCryst.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst Dives after Mixed Earnings
- BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
- BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
- BioCryst reports inducement grants under Nasdaq listing rule